200 related articles for article (PubMed ID: 20952131)
21. Trastuzumab cardio-oncology: lessons learned.
Frankel C
Clin J Oncol Nurs; 2010 Oct; 14(5):630-40. PubMed ID: 20880820
[TBL] [Abstract][Full Text] [Related]
22. [Cardiac safety of trastuzumab in adjuvant: a review across 53 observations].
Tanz R; Mahfoud T; Bazine A; Khmamouch R; Bensouda Y; Ismaili N; Benjaafar N; El Gueddari BK; Ichou M; Errihani H
J Gynecol Obstet Biol Reprod (Paris); 2011 Apr; 40(2):144-8. PubMed ID: 21227599
[TBL] [Abstract][Full Text] [Related]
23. Trastuzumab-related cardiac events in the treatment of early breast cancer.
Fried G; Regev T; Moskovitz M
Breast Cancer Res Treat; 2013 Nov; 142(1):1-7. PubMed ID: 24154507
[TBL] [Abstract][Full Text] [Related]
24. Cardiac toxicity in breast cancer patients treated with dual HER2 blockade.
Valachis A; Nearchou A; Polyzos NP; Lind P
Int J Cancer; 2013 Nov; 133(9):2245-52. PubMed ID: 23629633
[TBL] [Abstract][Full Text] [Related]
25. Clinical cardiac tolerability of trastuzumab.
Perez EA; Rodeheffer R
J Clin Oncol; 2004 Jan; 22(2):322-9. PubMed ID: 14722042
[TBL] [Abstract][Full Text] [Related]
26. Cardiac risk associated with the receipt of anthracycline and trastuzumab in a large nationwide cohort of older women with breast cancer, 1998-2005.
Du XL; Xia R; Burau K; Liu CC
Med Oncol; 2011 Dec; 28 Suppl 1():S80-90. PubMed ID: 20967512
[TBL] [Abstract][Full Text] [Related]
27. Trastuzumab-related cardiotoxicity: calling into question the concept of reversibility.
Telli ML; Hunt SA; Carlson RW; Guardino AE
J Clin Oncol; 2007 Aug; 25(23):3525-33. PubMed ID: 17687157
[TBL] [Abstract][Full Text] [Related]
28. Trastuzumab: a review of its use in the treatment of metastatic breast cancer overexpressing HER2.
McKeage K; Perry CM
Drugs; 2002; 62(1):209-43. PubMed ID: 11790161
[TBL] [Abstract][Full Text] [Related]
29. Cardiac dysfunction in the trastuzumab clinical trials experience.
Seidman A; Hudis C; Pierri MK; Shak S; Paton V; Ashby M; Murphy M; Stewart SJ; Keefe D
J Clin Oncol; 2002 Mar; 20(5):1215-21. PubMed ID: 11870163
[TBL] [Abstract][Full Text] [Related]
30. Assessment of cardiac dysfunction in a randomized trial comparing doxorubicin and cyclophosphamide followed by paclitaxel, with or without trastuzumab as adjuvant therapy in node-positive, human epidermal growth factor receptor 2-overexpressing breast cancer: NSABP B-31.
Tan-Chiu E; Yothers G; Romond E; Geyer CE; Ewer M; Keefe D; Shannon RP; Swain SM; Brown A; Fehrenbacher L; Vogel VG; Seay TE; Rastogi P; Mamounas EP; Wolmark N; Bryant J
J Clin Oncol; 2005 Nov; 23(31):7811-9. PubMed ID: 16258083
[TBL] [Abstract][Full Text] [Related]
31. Long-term cardiac tolerability of trastuzumab in metastatic breast cancer: the M.D. Anderson Cancer Center experience.
Guarneri V; Lenihan DJ; Valero V; Durand JB; Broglio K; Hess KR; Michaud LB; Gonzalez-Angulo AM; Hortobagyi GN; Esteva FJ
J Clin Oncol; 2006 Sep; 24(25):4107-15. PubMed ID: 16908934
[TBL] [Abstract][Full Text] [Related]
32. Assessment of adjuvant trastuzumab-associated cardiac toxicity in korean patients with breast cancer: a single-center analysis.
Cha C; Ahn SG; Lee HM; Lee HW; Lee SA; Jeong J
Oncology; 2013; 85(4):228-34. PubMed ID: 24081024
[TBL] [Abstract][Full Text] [Related]
33. Trastuzumab-associated cardiac adverse effects in the herceptin adjuvant trial.
Suter TM; Procter M; van Veldhuisen DJ; Muscholl M; Bergh J; Carlomagno C; Perren T; Passalacqua R; Bighin C; Klijn JG; Ageev FT; Hitre E; Groetz J; Iwata H; Knap M; Gnant M; Muehlbauer S; Spence A; Gelber RD; Piccart-Gebhart MJ
J Clin Oncol; 2007 Sep; 25(25):3859-65. PubMed ID: 17646669
[TBL] [Abstract][Full Text] [Related]
34. [Cardiac dysfunction induced by trastuzumab].
Campone M; Bourbouloux E; Fumoleau P
Bull Cancer; 2004 Nov; 91 Suppl 3():166-73. PubMed ID: 15899624
[TBL] [Abstract][Full Text] [Related]
35. Cardiovascular risk profile of patients with HER2/neu-positive breast cancer treated with anthracycline-taxane-containing adjuvant chemotherapy and/or trastuzumab.
Jones LW; Haykowsky M; Peddle CJ; Joy AA; Pituskin EN; Tkachuk LM; Courneya KS; Slamon DJ; Mackey JR
Cancer Epidemiol Biomarkers Prev; 2007 May; 16(5):1026-31. PubMed ID: 17507633
[TBL] [Abstract][Full Text] [Related]
36. Adjuvant trastuzumab in breast cancer: experience from the University of Florence.
Livi L; Borghesi S; Meattini I; Saieva C; De Luca Cardillo C; Scotti V; Mangoni M; Galardi A; Cataliotti L; Paiar F; Bianchi S; Biti G
J Chemother; 2010 Apr; 22(2):115-8. PubMed ID: 20435571
[TBL] [Abstract][Full Text] [Related]
37. Retrospective analysis of the safety of Herceptin immunotherapy in metastatic breast cancer.
Cook-Bruns N
Oncology; 2001; 61 Suppl 2():58-66. PubMed ID: 11694789
[TBL] [Abstract][Full Text] [Related]
38. Role of hypertension on new onset congestive heart failure in patients receiving trastuzumab therapy for breast cancer.
Russo G; Cioffi G; Gori S; Tuccia F; Boccardi L; Khoury G; Lestuzzi C; Maurea N; Oliva S; Faggiano P; Tarantini L;
J Cardiovasc Med (Hagerstown); 2014 Feb; 15(2):141-6. PubMed ID: 24534802
[TBL] [Abstract][Full Text] [Related]
39. Trastuzumab-associated cardiac events at 8 years of median follow-up in the Herceptin Adjuvant trial (BIG 1-01).
de Azambuja E; Procter MJ; van Veldhuisen DJ; Agbor-Tarh D; Metzger-Filho O; Steinseifer J; Untch M; Smith IE; Gianni L; Baselga J; Jackisch C; Cameron DA; Bell R; Leyland-Jones B; Dowsett M; Gelber RD; Piccart-Gebhart MJ; Suter TM
J Clin Oncol; 2014 Jul; 32(20):2159-65. PubMed ID: 24912899
[TBL] [Abstract][Full Text] [Related]
40. Is it safe to give anthracyclines concurrently with trastuzumab in neo-adjuvant or metastatic settings for HER2-positive breast cancer? A meta-analysis of randomized controlled trials.
Du F; Yuan P; Zhu W; Wang J; Ma F; Fan Y; Xu B
Med Oncol; 2014 Dec; 31(12):340. PubMed ID: 25416049
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]